Artículos por temáticas

Cerebrospinal Fluid Markers of Medium Spiny Neuron Injury in Huntington's Disease

Bang J, Ross CA.

Mov Disord. 2021 Feb;36(2):280-282. doi: 10.1002/mds.28386.

Prepubertal exposure to high dose of cadmium induces hypothalamic injury through transcriptome profiling alteration and neuronal degeneration in female rats

Saedi S, Jafarzadeh Shirazi MR, Niazi A, Tahmasebi A, Ebrahimie E.

Chem Biol Interact. 2021 Mar 1;337:109379. doi: 10.1016/j.cbi.2021.109379. Epub 2021 Jan 13.

CREB: A Multifaceted Target for Alzheimer's Disease

Sharma VK, Singh TG.

Curr Alzheimer Res. 2021 Feb 18. doi: 10.2174/1567205018666210218152253. Online ahead of print.

The development of PAT-HD: A co-designed tool to promote physical activity in people with Huntington's disease

Jones U, Hamana K, O'Hara F, Busse M.

Health Expect. 2021 Apr;24(2):638-647. doi: 10.1111/hex.13210. Epub 2021 Feb 13.

Coordinated roles of SLX4 and MutSβ in DNA repair and the maintenance of genome stability

Young SJ, West SC.

Crit Rev Biochem Mol Biol. 2021 Apr;56(2):157-177. doi: 10.1080/10409238.2021.1881433. Epub 2021 Feb 17.

Autonomic dysregulation as an early pathologic feature of Huntington Disease

Schultz JL, Harshman LA, Kamholz JA, Nopoulos PC.

Auton Neurosci. 2021 Mar;231:102775. doi: 10.1016/j.autneu.2021.102775. Epub 2021 Feb 5.

Proportional likelihood ratio mixed model for discrete longitudinal data

Wu H, Jones MP.

Stat Med. 2021 Apr;40(9):2272-2285. doi: 10.1002/sim.8902. Epub 2021 Feb 15.

Neurologists' current practice and perspectives on communicating the diagnosis of a motor neurodegenerative condition: a UK survey

Anestis E, Eccles FJR, Fletcher I, Simpson J.

BMC Neurol. 2021 Jan 22;21(1):34. doi: 10.1186/s12883-021-02062-6.

False-negative tests in Huntington's disease: A new variant within primer hybridization site

Dulski J, Sulek A, Krygier M, Radziwonik W, Slawek J.

Eur J Neurol. 2021 Jun;28(6):2103-2105. doi: 10.1111/ene.14772. Epub 2021 Mar 8.

A Novel Pharmacological Protective Role for Safranal in an Animal Model of Huntington's Disease

Fotoohi A, Moloudi MR, Hosseini S, Hassanzadeh K, Feligioni M, Izadpanah E.

Neurochem Res. 2021 Jun;46(6):1372-1379. doi: 10.1007/s11064-021-03271-8. Epub 2021 Feb 21.

Expression of glucose transporters in human neurodegenerative diseases

Głuchowska K, Pliszka M, Szablewski L.

Biochem Biophys Res Commun. 2021 Feb 12;540:8-15. doi: 10.1016/j.bbrc.2020.12.067. Epub 2021 Jan 8.

Moving beyond disease to function: Physiological roles for polyglutamine-rich sequences in cell decisions

Gerbich TM, Gladfelter AS.

Curr Opin Cell Biol. 2021 Apr;69:120-126. doi: 10.1016/j.ceb.2021.01.003. Epub 2021 Feb 18.

Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model

Huang ZN, Chen JM, Huang LC, Fang YH, Her LS.

Mol Neurobiol. 2021 Jun;58(6):2704-2723. doi: 10.1007/s12035-020-02280-y. Epub 2021 Jan 25.

Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice

Cano A, Ettcheto M, Espina M, Auladell C, Folch J, Kühne BA, Barenys M, Sánchez-López E, Souto EB, García ML, Turowski P, Camins A.

Nanomedicine (Lond). 2021 Jan;16(1):19-35. doi: 10.2217/nnm-2020-0239. Epub 2021 Jan 7.

Oligodendroglial Heterogeneity in Neuropsychiatric Disease

Bøstrand SMK, Williams A.

Life (Basel). 2021 Feb 6;11(2):125. doi: 10.3390/life11020125.